david m pernock executive profile  biography  bloomberg july    am et biotechnology company overview of eagle pharmaceuticals inc snapshotpeople  overviewboard memberscommittees executive profile david m pernock president and chief commercial officer eagle pharmaceuticals incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr david m pernock has been president and chief commercial officer at eagle pharmaceuticals inc since january   mr pernock served as the chairman of the board and chief executive officer of fibrocell science inc from september  and february   to december   and also served as its president until december   mr pernock served as the senior vice president of us pharmaceuticalsvaccines  biologics specialty businesses  philadelphia  for glaxosmithkline plc he served in a variety of executive capacities for glaxosmithkline gsk from  to  including senior vice president of pharmaceuticals vaccines biologics oncology acute care and hiv divisions vice president of marketing pharmaceuticals vice president of sales and marketing oncology vice president of sales and vice president of managed care mr pernock served as vice president of marketing wyeth pharmaceuticals and scheringplough corporation and vice president of sales and marketing at key pharmaceuticals mr pernock serves as a member of the advisory board of vatera capital llc he serves as a member of the advisory board at vatera healthcare partners he served as alliance for regenerative medicine since december  he served as an director of eagle pharmaceuticals inc from april   to january   he serves as a director of greater philadelphia chamber of commerce mr pernock served as a director of fibrocell science inc from september  to december   he served as a director of martek biosciences corp since september  he was a presenter at the rd annual regenerative medicine partnering forum part of this years stem cell meeting on the mesa held in la jolla california organized by the alliance for regenerative medicine arm the california institute for regenerative medicine cirm and the sanford consortium for regenerative medicine the  stem cell meeting on the mesa was a threeday conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures mr pernock holds a bachelor of science degree in business administration from arizona state universityread full background corporate headquarters  tice boulevardwoodcliff lake new jersey united statesphone fax  board members memberships directorgreater philadelphia chamber of commercepresentdirectoralliance for regenerative medicine education bsba arizona state universitytempe other affiliations martek biosciences corporationfibrocell science incarizona state universitytempegreater philadelphia chamber of commercevatera healthcare partnersalliance for regenerative medicine annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation total annual cash compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationfriedhelm blobel phdchief executive officer president and executive directorsciclone pharmaceuticals inckrajesh c shrotriya mdchairman and chief executive officerspectrum pharmaceuticals incmjohn f thero chief executive officer president and directoramarin corporation plckkimberly j popovits chairman chief executive officer and presidentgenomic health incksaeed motahari president ceo  directorinsys therapeutics inccompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact eagle pharmaceuticals inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close eagle pharma announces david pernock as president and chief commercial officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       eagle pharma egrx announces david pernock as president and chief commercial officer tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs woodcliff lake njbusiness wireeagle pharmaceuticals inc “eagle” or “the company” nasdaqegrx today announced that david pernock will join eagle as president and chief commercial officer effective january  mr pernock brings vast experience in pharmaceutical and biotechnology leadership to the company he will be responsible for all commercial strategy and execution for eagle’s growing product portfolio including the launch of expanded indications for ryanodex® for exertional heat stroke “ehs” and drug induced hyperthermia if approved by the food and drug administration “fda” mr pernock will report to scott tarriff eagle’s chief executive officer “david has a distinguished track record as a leader in the pharmaceutical sector during his tenure at glaxosmithkline he brought multiple blockbuster drugs to market and led strategic direction and operational success across diverse businesses and most recently served as the ceo of a publiclytraded gene therapy biotechnology company his appointment fortifies our management team and underscores eagle’s commitment to the success of our growing portfolio and the opportunities we see in our pipeline such as the label expansion of ryanodex for the treatment of exertional heat stroke a nearterm opportunity if approved by the fda this would be a very significant product launch for the company and we are thrilled to have someone of david’s caliber to lead its success” stated scott tarriff “as an eagle board member i became deeply familiar with the company’s pipeline and prospects which led me to make the decision to take this position this new role reflects my enthusiasm for and confidence in eagles future i look forward to joining the eagle team to lead the expanded commercial efforts for ryanodex following approval and multiple additional potential product launches in the future if approved ryanodex for ehs would address the needs of new patient populations for whom no pharmaceutical treatment options are currently available we view the potential launch of ryanodex as a very significant opportunity and are committed to allocating the resources required to help ensure a successful commercial launch” added david pernock david pernock has been a member of eagle’s board of directors since april  mr pernock will relinquish his eagle board position effective january  in connection with his new role as president and chief commercial officer about david pernock david pernock is a pharmaceutical and biotechnology industry expert he has served as a member of eagle’s board of directors since april  mr pernock most recently served as chairman of the board of directors and chief executive officer  of fibrocell nasdaq fcsc an autologous cell and gene therapy company previously he held various positions at glaxosmithkline plc gsk most notably serving as senior vice president of pharmaceuticals vaccines biologics oncology acute care and hiv divisions mr pernock served as president of reliant pharmaceuticals when reliant was acquired by gsk he was president of smithkline beechampuerto rico prior to the gsk merger furthermore mr pernock served as a director of martek biosciences corporation about eagle pharmaceuticals inc eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially successful injectable products eagle’s strategy is to utilize the fdas b regulatory pathway additional information is available on the company’s website at wwweagleuscom about ryanodex® ryanodex dantrolene sodium for injectable suspension is indicated for the treatment of malignant hyperthermia “mh” in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk forwardlooking statements this press release contains forwardlooking information within the meaning of the private securities litigation reform act of  as amended and other securities laws forwardlooking statements are statements that are not historical facts words such as “anticipated” “drive” “will” “growing” “we see” “near term” “would” “lead” “future” “potential” “committed” and similar expressions are intended to identify forwardlooking statements these statements include statements regarding future events including but not limited to the impact if any that the appointment of a new officer will have on eagle’s business the ability of this new officer to effectively leverage his expertise and experience to expand eagle’s reach and value the ability of eagle to continue to expand its product portfolio as well as to maximize the value of its commercial products the earnings potential and longterm value of ryanodex the safety and efficacy of ryanodex for the treatment of exertional heat stroke “ehs” fda approval of the use of ryanodex for the treatment of ehs difficulties or delays in manufacturing the availability and pricing of third party sourced products and materials successful compliance with fda and other governmental regulations applicable to manufacturing facilities products andor businesses the ability of eagle to deliver sustained shareholder value over time and other factors that are discussed in eagle’s annual report on form k for the year ended december   as amended and its other filings with the us securities and exchange commission all of such statements are subject to certain risks and uncertainties many of which are difficult to predict and generally beyond eagle’s control that could cause actual results to differ materially from those expressed in or implied or projected by the forwardlooking information and statements such risks include but are not limited to whether eagle’s management andor board of directors will be effective in managing eagle’s business and future growth whether eagle will generate earnings and realize longterm value from ryanodex whether the fda will ultimately approve ryanodex for the treatment of ehs whether our studies will support the safety and efficacy of ryanodex for the treatment of ehs as well as the other risks described in eagle’s filings with the us securities and exchange commission readers are cautioned not to place undue reliance on these forwardlooking statements that speak only as of the date hereof and we do not undertake any obligation to revise and disseminate forwardlooking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of or nonoccurrence of any events investor relations for eagle pharmaceuticals incinsite communications inclisa m wilson lwilsoninsiteconycom read at biospacecom related news eagle pharma egrx reports positive results from pivotal animal study supporting the efficacy of ryanodex for exertional heat stroke fdas woodcock speaks about one of the agencys most controversial decisions eagle pharma egrx snaps up massachusetts arsia in  million deal after ceo ouster interim alexion alxn boss says we need to move on eagle pharma egrx announces positive initial results of animal study exploring use of ryanodex in mdma ecstasy induced hyperthermia conducted at nih obamas science adviser explains why a sciencesavvy president matters eagle pharma egrx and teva teva release centers for medicare  medicaid services establishes unique jcode for bendeka bendamustine hydrochloride injection the  best biopharma ceos of  are eagle pharma egrx reports third quarter  results fibrocell fcsc appoints new chief executive officer please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • eagle pharmaceuticals   • biotechpharma  personnel                 eagle pharmaceuticals announces david pernock as president and chief commercial officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street eagle pharmaceuticals announces david pernock as president and chief commercial officer business wire dec    am est eagle pharmaceuticals inc eagle or the company nasdaqegrx today announced that david pernock will join eagle as president and chief commercial officer effective january  mr pernock brings vast experience in pharmaceutical and biotechnology leadership to the company he will be responsible for all commercial strategy and execution for eagles growing product portfolio including the launch of expanded indications for ryanodex® for exertional heat stroke ehs and drug induced hyperthermia if approved by the food and drug administration fda mr pernock will report to scott tarriff eagles chief executive officer david has a distinguished track record as a leader in the pharmaceutical sector during his tenure at glaxosmithkline he brought multiple blockbuster drugs to market and led strategic direction and operational success across diverse businesses and most recently served as the ceo of a publiclytraded gene therapy biotechnology company his appointment fortifies our management team and underscores eagles commitment to the success of our growing portfolio and the opportunities we see in our pipeline such as the label expansion of ryanodex for the treatment of exertional heat stroke a nearterm opportunity if approved by the fda this would be a very significant product launch for the company and we are thrilled to have someone of davids caliber to lead its success stated scott tarriff as an eagle board member i became deeply familiar with the companys pipeline and prospects which led me to make the decision to take this position this new role reflects my enthusiasm for and confidence in eagles future i look forward to joining the eagle team to lead the expanded commercial efforts for ryanodex following approval and multiple additional potential product launches in the future if approved ryanodex for ehs would address the needs of new patient populations for whom no pharmaceutical treatment options are currently available we view the potential launch of ryanodex as a very significant opportunity and are committed to allocating the resources required to help ensure a successful commercial launch added david pernock if you liked this article you might like three healthcare growth plays eagle pharmaceuticals invitae and celgene should do well this year and are attractively priced bret jensen jan    am est  smallcaps bucking the downtrend news announcements from these companies are supportive of continued strength bret jensen nov    am edt  smallcaps bucking the downtrend news announcements from these companies is supportive of continued strength bret jensen nov    am edt how to play it when the fda slams your stock here are three recent examples of how the patient can profit bret jensen sep    am edt trending ftc seen as set to block rite aid deal  foods to avoid if you have high cholesterol it would be crazy to clean house at wells fargo ceo says mcdonalds has a restaurant in poland that looks like the future of the golden arches amazons earnings miss but nothing can stop aws advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers eagle pharmaceuticals announces david pernock as president and chief commercial officer  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings press release dec    am est eagle pharmaceuticals announces david pernock as president and chief commercial officer  experienced commercial leader hired to strengthen anticipated product launches and drive commercial success ryanodex label expansion launch to be initial focus if approved by the fda  woodcliff lake nj dec   business wire  eagle pharmaceuticals inc “eagle” or “the company” quoteszigmancomposite egrx  today announced that david pernock will join eagle as president and chief commercial officer effective january  mr pernock brings vast experience in pharmaceutical and biotechnology leadership to the company he will be responsible for all commercial strategy and execution for eagle’s growing product portfolio including the launch of expanded indications for ryanodex® for exertional heat stroke “ehs” and drug induced hyperthermia if approved by the food and drug administration “fda” mr pernock will report to scott tarriff eagle’s chief executive officer “david has a distinguished track record as a leader in the pharmaceutical sector during his tenure at glaxosmithkline he brought multiple blockbuster drugs to market and led strategic direction and operational success across diverse businesses and most recently served as the ceo of a publiclytraded gene therapy biotechnology company his appointment fortifies our management team and underscores eagle’s commitment to the success of our growing portfolio and the opportunities we see in our pipeline such as the label expansion of ryanodex for the treatment of exertional heat stroke a nearterm opportunity if approved by the fda this would be a very significant product launch for the company and we are thrilled to have someone of david’s caliber to lead its success” stated scott tarriff “as an eagle board member i became deeply familiar with the company’s pipeline and prospects which led me to make the decision to take this position this new role reflects my enthusiasm for and confidence in eagles future i look forward to joining the eagle team to lead the expanded commercial efforts for ryanodex following approval and multiple additional potential product launches in the future if approved ryanodex for ehs would address the needs of new patient populations for whom no pharmaceutical treatment options are currently available we view the potential launch of ryanodex as a very significant opportunity and are committed to allocating the resources required to help ensure a successful commercial launch” added david pernock david pernock has been a member of eagle’s board of directors since april  mr pernock will relinquish his eagle board position effective january  in connection with his new role as president and chief commercial officer about david pernock david pernock is a pharmaceutical and biotechnology industry expert he has served as a member of eagle’s board of directors since april  mr pernock most recently served as chairman of the board of directors and chief executive officer  of fibrocell quoteszigmancomposite fcsc   an autologous cell and gene therapy company previously he held various positions at glaxosmithkline plc gsk most notably serving as senior vice president of pharmaceuticals vaccines biologics oncology acute care and hiv divisions mr pernock served as president of reliant pharmaceuticals when reliant was acquired by gsk he was president of smithkline beechampuerto rico prior to the gsk merger furthermore mr pernock served as a director of martek biosciences corporation about eagle pharmaceuticals inc eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially successful injectable products eagle’s strategy is to utilize the fdas b regulatory pathway additional information is available on the company’s website at wwweagleuscom  about ryanodex ® ryanodex dantrolene sodium for injectable suspension is indicated for the treatment of malignant hyperthermia “mh” in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk forwardlooking statements this press release contains forwardlooking information within the meaning of the private securities litigation reform act of  as amended and other securities laws forwardlooking statements are statements that are not historical facts words such as “anticipated” “drive” “will” “growing” “we see” “near term” “would” “lead” “future” “potential” “committed” and similar expressions are intended to identify forwardlooking statements these statements include statements regarding future events including but not limited to the impact if any that the appointment of a new officer will have on eagle’s business the ability of this new officer to effectively leverage his expertise and experience to expand eagle’s reach and value the ability of eagle to continue to expand its product portfolio as well as to maximize the value of its commercial products the earnings potential and longterm value of ryanodex the safety and efficacy of ryanodex for the treatment of exertional heat stroke “ehs” fda approval of the use of ryanodex for the treatment of ehs difficulties or delays in manufacturing the availability and pricing of third party sourced products and materials successful compliance with fda and other governmental regulations applicable to manufacturing facilities products andor businesses the ability of eagle to deliver sustained shareholder value over time and other factors that are discussed in eagle’s annual report on form k for the year ended december   as amended and its other filings with the us securities and exchange commission all of such statements are subject to certain risks and uncertainties many of which are difficult to predict and generally beyond eagle’s control that could cause actual results to differ materially from those expressed in or implied or projected by the forwardlooking information and statements such risks include but are not limited to whether eagle’s management andor board of directors will be effective in managing eagle’s business and future growth whether eagle will generate earnings and realize longterm value from ryanodex whether the fda will ultimately approve ryanodex for the treatment of ehs whether our studies will support the safety and efficacy of ryanodex for the treatment of ehs as well as the other risks described in eagle’s filings with the us securities and exchange commission readers are cautioned not to place undue reliance on these forwardlooking statements that speak only as of the date hereof and we do not undertake any obligation to revise and disseminate forwardlooking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of or nonoccurrence of any events view source version on businesswirecom httpwwwbusinesswirecomnewshomeen source eagle pharmaceuticals inc investor relations for eagle pharmaceuticals inc insite communications inc lisa m wilson  lwilsoninsiteconycom copyright business wire  quoteszigmancomposite add to watchlist egrx eagle pharmaceuticals inc us  us nasdaq     volume  july   p pe ratio dividend yieldna market cap million rev per employeem quoteszigmancomposite add to watchlist fcsc fibrocell science inc us  us nasdaq     volume  july   p pe rationa dividend yieldna market cap million rev per employee most popular  the dark side of cruises  cocacola to replace coke zero in us  market snapshot dow ends at record but tech slump weighs on sp  nasdaq  if you can buy only one stock or etf make it this one  barrons buzz how to fix wall street and bankers pay find a broker partner center » featured stories seeing america again through new eyes how to dig yourself out of debt move over tesla karma unveils its hybrid sports car the salary you need to afford a home in these  cities why opec will never cut production again log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abritishmade seedlip aims to woo the nondrinking crowd aset yourself up to get the most out of retirement aeuropean stocks sell off as ubs falls tech worries weigh aprince william and kate middleton are hiring— though not for these weird five royal family jobs arightmove profit rises on ad sales abank of ireland profit falls to restart dividend ahow do i get a reverse mortgage aus tech stocks shape up for another day of selling after amazon disappoints athis city’s subway system will soon run entirely on renewable energy a‘skinny’ repeal of obamacare fails to pass in latenight senate vote aubs credit suisse profit up after strategic shift arenault firsthalf profit leaps on higher volume aftse  under pressure as bt pushed lower afrances cac  falls  dropping further in early friday trade abarclays falls  after earnings report abritish airways parent iag rises  after quarterly profit report abritish airways parent iags profit soars agermanys dax opens  lower at  afrances cac  opens  lower at  alinde profit slides on restructuring costs loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft pernock david  the wall street transcript david pernock david pernock serves as fibrocell science inc’s chairman of the board and chief executive officer previously he held various positions at glaxosmithkline or gsk most notably serving as senior vice president of pharmaceuticals vaccines biologics oncology acute care and hiv divisions prior to that mr pernock served as president of reliant pharmaceuticals when reliant was acquired by gsk he was president of smithkline beecham—puerto rico prior to the gsk merger furthermore mr pernock served as a director of martek biosciences corporation and is currently a member of the board of directors for eagle pharmaceuticals inc nasdaqegrx mr pernock holds a bs in business administration from arizona state university related interviewsinterview with the chairman and ceo fibrocell science inc nasdaqfcscapril   cartlatest newsall american usc footbal player joseph m boskovich jr now picks all american value stocks for his clientspaul hogan picks tech dividend growers microchip technology nasdaqmchp xilinx nasdaqxlnx and versum materials nysevsm gallons of water to produce a mcdonalds nysemcd quarter pounder how will investors profitthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsbuilding diversified portfolios with quality global equitiesgregory d padillaalberto jimenez crespo published july   in investing strategiescompanies covered amzn  aapl mu whr kimbera gs vod ppg shw viv pey buy building accountability and avoiding mistakes through the decision processdean pagonis published july   in investing strategiescompanies covered cmp sbh amzn ulta cvs lrlcy kmb www sdf buy finding optimal balance sheets by utilizing high yield market expertisezach miller published july   in investing strategiescompanies covered lsxmk siri bll chtr armk buy most popular reportsinvesting strategies published july  buy wireless communications  telecom published july  buy investing strategies published july  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsbuilding diversified portfolios with quality global equitiesbuilding accountability and avoiding mistakes through the decision processfinding optimal balance sheets by utilizing high yield market expertise analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google eagle pharmaceuticals announces david pernock as president and chief commercial officer  new jersey business magazine eagle pharmaceuticals announces david pernock as president and chief commercial officer  new jersey business magazine home about us meet our staff njbia media profile archives issue archives article archives virtual issue special sections subscribe annual subscription single issue virtual issue adops media kit young professionals contact us new jersey business   blog facebook twitter google linkedin eagle pharmaceuticals announces david pernock as president and chief commercial officer  new jersey business magazine menu njb  njb news now  eagle pharmaceuticals announc… eagle pharmaceuticals announces david pernock as president and chief commercial officer dec   no comments eagle pharmaceuticals inc with an office in woodcliff lake announced that david pernock will join eagle as president and chief commercial officer effective january  mr pernock brings vast experience in pharmaceutical and biotechnology leadership to the company he will be responsible for all commercial strategy and execution for eagle’s growing product portfolio including the launch of expanded indications for ryanodex® for exertional heat stroke “ehs” and drug induced hyperthermia if approved by the food and drug administration mr pernock will report to scott tarriff eagle’s chief executive officer “david has a distinguished track record as a leader in the pharmaceutical sector during his tenure at glaxosmithkline he brought multiple blockbuster drugs to market and led strategic direction and operational success across diverse businesses and most recently served as the ceo of a publiclytraded gene therapy biotechnology company his appointment fortifies our management team and underscores eagle’s commitment to the success of our growing portfolio and the opportunities we see in our pipeline such as the label expansion of ryanodex for the treatment of exertional heat stroke a nearterm opportunity if approved by the fda this would be a very significant product launch for the company and we are thrilled to have someone of david’s caliber to lead its success” stated scott tarriff “as an eagle board member i became deeply familiar with the company’s pipeline and prospects which led me to make the decision to take this position this new role reflects my enthusiasm for and confidence in eagle’s future i look forward to joining the eagle team to lead the expanded commercial efforts for ryanodex following approval and multiple additional potential product launches in the future if approved ryanodex for ehs would address the needs of new patient populations for whom no pharmaceutical treatment options are currently available we view the potential launch of ryanodex as a very significant opportunity and are committed to allocating the resources required to help ensure a successful commercial launch” added david pernock david pernock has been a member of eagle’s board of directors since april  mr pernock will relinquish his eagle board position effective january  in connection with his new role as president and chief commercial officer tags david pernockeagle pharmaceuticalsnew jerseypharmaceuticalswoodcliff lake jetpackrelatedposts new jersey business today join our daily enews service timely news and information delivered to your inbox at  pm weekdays and at  am on saturday morning njb news now rwjbarnabas health and rutgers university announce new partn  jul   no comments astrazeneca and merck establish strategic oncology collabora  jul   no comments somerset firm is named sba regional subcontractor of the yea  jul   no comments more news › news tracker amazon hiring k across us including in nj njcom if you build a warehouse in new jersey they will come… njspotlightcom the senate agreed to debate a health care bill now what northjerseycom more news › njbia zone lt gov candidates named by murphy and guadagno jul   nj best state for business loan approvals online lending company says jul   njbia honored by asae for influential outmigration report jul   more from njbia › view virtual issue eagle pharmaceuticals appoints david m pernock to its board of directors  eagle pharmaceuticals investor center toggle navigation menu investors login eagle pharmaceuticals appoints david m pernock to its board of directors monday april    am edt dateline woodcliff lake nj emailpdfprintrss public company information nasdaqegrxus we are very pleased to welcome him to our board woodcliff lake njbusiness wireeagle pharmaceuticals inc nasdaqegrx “eagle” or “the company” today announced that david m pernock an experienced biotechnology and pharmaceutical executive with over  years of industry experience has been appointed to its board of directors effective immediately “david pernock is a proven leader and brings a wealth of knowledge and experience within our industry which we will look to draw upon as we execute our strategy and drive growth for our shareholders” commented scott tarriff president and ceo of eagle pharmaceuticals “we are very pleased to welcome him to our board” mr pernock is chief executive officer and chairman of the board of fibrocell science inc a biotechnology company developing autologous therapeutics for skin and connective tissue diseases prior to fibrocell mr pernock held several positions during his year tenure at glaxosmithkline including senior vice president of pharmaceuticals vaccines biologics oncology acute care and hiv divisions vice president of marketing pharmaceuticals vice president of sales and marketing oncology vice president of sales and vice president of managed care previously mr pernock was vice president of marketing wyeth pharmaceuticals and scheringplough corporation and vice president of sales and marketing at key pharmaceuticals in addition to his role as chairman of the board of fibrocell science inc mr pernock served on the boards of martek biosciences corporation and the alliance for regenerative medicine mr pernock was elected to fill a vacancy on the board and will serve as a class i director with a term of office expiring at the company’s  annual meeting of stockholders about eagle pharmaceuticals inc eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially successful injectable products eagle’s strategy is to utilize the fdas b regulatory pathway additional information is available on the company’s website at wwweagleuscom forwardlooking statements this press release contains forwardlooking information within the meaning of the private securities litigation reform act of  as amended and other securities laws forwardlooking statements are statements that are not historical facts words such as “will” “may” “intends” “anticipates” “plan” “enables” “potentially” “entitles” and similar expressions are intended to identify forwardlooking statements these statements include but are not limited to statements regarding future events including but not limited to difficulties or delays in manufacturing the availability and pricing of third party sourced products and materials successful compliance with fda and other governmental regulations applicable to manufacturing facilities products andor businesses and other factors that are discussed in eagle’s annual report on form k for the year ended september   and its other filings with the us securities and exchange commission all of such statements are subject to certain risks and uncertainties many of which are difficult to predict and generally beyond eagle’s control that could cause actual results to differ materially from those expressed in or implied or projected by the forwardlooking information and statements such risks include but are not limited to risks described in eagle’s filings with the us securities and exchange commission readers are cautioned not to place undue reliance on these forwardlooking statements that speak only as of the date hereof and we do not undertake any obligation to revise and disseminate forwardlooking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of or nonoccurrence of any events contact insite communications inclisa m wilson president nasdaq egrxstock info    minimum  minute delayrefresh data investor center home press releases corporate governance stock information sec filings events  presentations analyst coverage investor faqs investor contacts search search this site advanced search registration login media requests email alerts rss feeds eagle pharmaceuticals announces david pernock as president and chief commercial officerhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hrs  minssp futures dow futures nasdaq futures eagle pharmaceuticals announces david pernock as president and chief commercial officerbusiness wiredecember  reblogsharetweetsharewoodcliff lake njbusiness wireeagle pharmaceuticals inc “eagle” or “the company” egrx today announced that david pernock will join eagle as president and chief commercial officer effective january  mr pernock brings vast experience in pharmaceutical and biotechnology leadership to the company he will be responsible for all commercial strategy and execution for eagle’s growing product portfolio including the launch of expanded indications for ryanodex® for exertional heat stroke “ehs” and drug induced hyperthermia if approved by the food and drug administration “fda” mr pernock will report to scott tarriff eagle’s chief executive officer“david has a distinguished track record as a leader in the pharmaceutical sector during his tenure at glaxosmithkline he brought multiple blockbuster drugs to market and led strategic direction and operational success across diverse businesses and most recently served as the ceo of a publiclytraded gene therapy biotechnology company his appointment fortifies our management team and underscores eagle’s commitment to the success of our growing portfolio and the opportunities we see in our pipeline such as the label expansion of ryanodex for the treatment of exertional heat stroke a nearterm opportunity if approved by the fda this would be a very significant product launch for the company and we are thrilled to have someone of david’s caliber to lead its success” stated scott tarriff“as an eagle board member i became deeply familiar with the company’s pipeline and prospects which led me to make the decision to take this position this new role reflects my enthusiasm for and confidence in eagles future i look forward to joining the eagle team to lead the expanded commercial efforts for ryanodex following approval and multiple additional potential product launches in the future if approved ryanodex for ehs would address the needs of new patient populations for whom no pharmaceutical treatment options are currently available we view the potential launch of ryanodex as a very significant opportunity and are committed to allocating the resources required to help ensure a successful commercial launch” added david pernockdavid pernock has been a member of eagle’s board of directors since april  mr pernock will relinquish his eagle board position effective january  in connection with his new role as president and chief commercial officerabout david pernockdavid pernock is a pharmaceutical and biotechnology industry expert he has served as a member of eagle’s board of directors since april  mr pernock most recently served as chairman of the board of directors and chief executive officer  of fibrocell fcsc an autologous cell and gene therapy company previously he held various positions at glaxosmithkline plc gsk most notably serving as senior vice president of pharmaceuticals vaccines biologics oncology acute care and hiv divisions mr pernock served as president of reliant pharmaceuticals when reliant was acquired by gsk he was president of smithkline beechampuerto rico prior to the gsk merger furthermore mr pernock served as a director of martek biosciences corporationabout eagle pharmaceuticals inceagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially successful injectable products eagle’s strategy is to utilize the fdas b regulatory pathway additional information is available on the company’s website at wwweagleuscomabout ryanodex®ryanodex dantrolene sodium for injectable suspension is indicated for the treatment of malignant hyperthermia “mh” in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high riskforwardlooking statementsthis press release contains forwardlooking information within the meaning of the private securities litigation reform act of  as amended and other securities laws forwardlooking statements are statements that are not historical facts words such as “anticipated” “drive” “will” “growing” “we see” “near term” “would” “lead” “future” “potential” “committed” and similar expressions are intended to identify forwardlooking statements these statements include statements regarding future events including but not limited to the impact if any that the appointment of a new officer will have on eagle’s business the ability of this new officer to effectively leverage his expertise and experience to expand eagle’s reach and value the ability of eagle to continue to expand its product portfolio as well as to maximize the value of its commercial products the earnings potential and longterm value of ryanodex the safety and efficacy of ryanodex for the treatment of exertional heat stroke “ehs” fda approval of the use of ryanodex for the treatment of ehs difficulties or delays in manufacturing the availability and pricing of third party sourced products and materials successful compliance with fda and other governmental regulations applicable to manufacturing facilities products andor businesses the ability of eagle to deliver sustained shareholder value over time and other factors that are discussed in eagle’s annual report on form k for the year ended december   as amended and its other filings with the us securities and exchange commission all of such statements are subject to certain risks and uncertainties many of which are difficult to predict and generally beyond eagle’s control that could cause actual results to differ materially from those expressed in or implied or projected by the forwardlooking information and statements such risks include but are not limited to whether eagle’s management andor board of directors will be effective in managing eagle’s business and future growth whether eagle will generate earnings and realize longterm value from ryanodex whether the fda will ultimately approve ryanodex for the treatment of ehs whether our studies will support the safety and efficacy of ryanodex for the treatment of ehs as well as the other risks described in eagle’s filings with the us securities and exchange commission readers are cautioned not to place undue reliance on these forwardlooking statements that speak only as of the date hereof and we do not undertake any obligation to revise and disseminate forwardlooking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of or nonoccurrence of any eventsview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nextvirgin atlantic founder sir richard branson sells pc stake in airline for £m as part of new tieup with air franceklmthe telegraphthis will be in everyones household by banyan hillsponsoredwind projects in peril as indian states rethink purchasesbloombergamazon surpasses b mark bezos briefly becomes the world’s richest personinvestopediaflights to hawaii are about to get so much cheaperrefineryzuckerberg wifes ambitious secret finally exposedunewzmesponsoredwework raised  million to expand in chinabusiness insider uktrump’s unwitting legacy could be universal health coverageyahoo financesean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredmattis was on vacation when trump tweeted transgender ban and he was reportedly appalled by itbusiness insidertwitter is only famous now because of president trump nyse traderyahoo finance videogdp — what you need to know in markets on fridayyahoo financediscover it  out of  avg by k customersdiscover cardsponsoredrepublicans kill the border taxyahoo financeamazon ploughs ahead with high sales and spending profit plungesreutersdonald trump hovers over melania during a speech as only trump cananonymous i put  years in the service  i find it nearly impossible to feel even an inkling of patriotism when i see this potus adorning any military patch or regalia he violates his oath he hates so many classes of people he does not understand classified categories mean he does not know the difference between taking up arms and bullying people or nations absolutely relieved that i would not have to put my life on the line for a person who believes there is no line between right and wrong god save and bless americajoin the conversation  k